非小细胞肺癌EGFR基因突变与ERCC1、RRM1、TUBB3 mRNA表达相关性研究
| 作者: |
1文苗苗,
1邢昊,
1王雪娇,
1李维妙,
1王磊,
1孙盈,
1夏靖华,
1张志培,
1李小飞
1 第四军医大学唐都医院胸腔外科，西安 710038 |
| 通讯: |
张志培
Email: zzpzyy@fmmu.edu.cn 李小飞 Email: lxfchest@fmmu.edu.cn |
| DOI: | 10.3978/j.issn.2095-6959.2016.01.010 |
摘要
目的：探讨非小细胞肺癌(non-small cell lung cancer，NSCLC)患者表皮生长因子受体(epidermal growth factor receptor，EGFR)基因突变与切除修复交叉互补蛋白1(excision repair cross-complementation 1，ERCC1)、核苷酸还原酶亚单位M1(ribonucleotide reductase subunit M1，RRM1)及3型β-微管蛋白基因(class Ⅲ β-tubulin，TUBB3)表达的关系。方法：回顾性分析我院经病理诊断的69例NSCLC患者的手术切除的肿瘤标本，利用扩增受阻突变系统(amplification refractory mutation system，ARMS)进行EGFR基因突变检测，应用实时荧光定量PCR检测ERCC1、RRM1及TUBB3 mRNA的表达水平。结果：69例患者中，EGFR突变率为33.33%(23/69)，在性别、吸烟史、病理类型组间突变率有显著性差异。ERCC1低、高表达率分别为59.42%(41/69)、40.58%(28/69)，EGFR突变与ERCC1表达呈负相关性，EGFR无突变时ERCC1趋向于高表达(P=0.024)；RRM1低、高表达率分别为31.88%(22/69)、68.12%(47/69)，EGFR突变与RRM1表达无相关性(P>0.05)；TUBB3低、高表达率分别为8.70%(6/69)、91.30%(63/69)，EGFR突变与TUBB3表达无相关性(P>0.05)。ERCC1、RRM1、TUBB3三者间的基因表达均无相关性。结论：NSCLC患者肿瘤组织中EGFR突变患者ERCC1倾向低表达，这类患者可能更能从铂类化疗和靶向药物中受益。
关键词：
非小细胞肺癌
表皮生长因子受体
切除修复交叉互补蛋白1
3型β-微管蛋白基因
分子检测
Association of EGFR mutation with the mRNA expression of ERCC1, RRM1 and TUBB in non-small cell lung cancer tissues
CorrespondingAuthor: ZHANG Zhipei Email: zzpzyy@fmmu.edu.cn
DOI: 10.3978/j.issn.2095-6959.2016.01.010
Abstract
Objective: To better understand the correlation between EGFR mutation and the expression of several biomarkers, including ERCC1, RRM1, TUBB3. Methods: A total of 69 NSCLC cases were analyzed concurrently for EGFR mutations and mRNA expression of the ERCC1, RRM1, TUBB3 genes. EGFR mutation was detected by amplified refractory mutation system (ARMS), mRNA expression of the ERCC1, RRM1, TUBB3 genes were detected by real time polymerase chain reaction analysis (RT-PCR). Results: Among the 69 NSCLC cases screened for this study, EGFR mutation rate was found in 33.33% (23/69), there was a significant difference in gender, smoking status, histology. The low and high mRNA levels of ERCC1 were 59.42% (41/69) and 40.58% (28/69), respectively. EGFR mutation expression was negative correlation with ERCC1 expression (P=0.024). The low and high expression rates of RRM1 were 31.88% (22/69), 68.12% (47/69), respectively. EGFR mutation was not correlation with the expression of RRM1 (P>0.05); the low and high expression rates of TUBB3 were 8.70% (6/69), 91.30% (63/69) respectively. There was no significant correlation between EGFR mutation and the expression of TUBB3 (P>0.05). Also there was no relationship among the expressions of ERCC1, RRM1 and TUBB3. Conclusion: Low ERCC1 expression is more likely to be expressed with EGFR mutation in NSCLC, who may benefit from the platinum-based chemotherapy and TKI.